Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 311

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 311
---
 convertible loan in the aggregate
amount of $835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the Company of the same
class of the conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 88,385 Ordinary Shares and the
warrants granted thereunder expired in full in December 2023.

Between October 2024
and November 2024, we entered into Bridge Loans, pursuant to which we obtained a bridge loan from certain lenders, including certain
related parties. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans have been extended until August 31,
2025 and during September 2025, the Bridge Loans were further extended to November 30, 2025, and shall bear interest at 8% per annum
until maturity commencing as of September 1, 2024. Furthermore, upon the occurrence of a Qualified IPO, the Bridge Loan lenders,
shall be granted warrants to purchase such number of Ordinary Shares equal to 140,000 Ordinary Shares following the consummation of
this offering.

Between December 2023
and January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000
from certain lenders, including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the
2024 Loan Agreements have been extended until August 31, 2025, and during September 2025, the 2024 Loan Agreements were further
extended to November 30, 2025, and shall bear interest at 8% per annum until maturity commencing as of September 1, 2024.
Furthermore, upon the occurrence of a Qualified IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase such
number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 61,538 Ordinary Shares following the consummation of this offering.

On December 1, 2024,
we entered into the December 2024 Loan Agreement with our Chief Executive Officer, according to which accrued payroll salary owed to
him in the aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at an 8% annual rate, and